Peptides for testosterone replacement FAQ

Start HCG at 500 IU three times weekly and expect gradual recovery over 12–18 months, not weeks. Testicular volume may increase 10–15% within the first three months, but full recovery to baseline is uncommon once atrophy exceeds 30%. A 2021 study from the University of Utah found that men who added HCG after 12+ months of testosterone monotherapy regained an average of 8% testicular volume after 24 months of HCG use. Significant but not complete reversal. If fertility is the goal, add recombinant FSH (75–150 IU three times weekly) alongside HCG to accelerate spermatogenic recovery.

Reduce the HCG dose first. Estradiol elevation on HCG is dose-dependent. Intratesticular testosterone is aromatised locally, and HCG doses above 500 IU per injection drive excessive conversion. Drop to 250 IU every other day and retest estradiol in four weeks. If estradiol remains >50 pg/mL after dose reduction, a low-dose aromatase inhibitor (0.25–0.5mg anastrozole twice weekly) can be added, but our experience shows most cases resolve with HCG dose adjustment alone. Over-suppressing estradiol (<20 pg/mL) negatively affects lipid profiles, bone density, and mood. Aromatase inhibitors should be the last adjustment, not the first.

HCG alone preserves fertility in 50–65% of men on TRT, which is better than the 8% success rate with testosterone monotherapy. Adding recombinant FSH (not a peptide, but mechanistically necessary for spermatogenesis) increases that figure to 75–80%. The protocol: HCG 250 IU every other day + FSH 75 IU three times weekly. Monitor semen analysis every 12 weeks. If sperm count remains above 5 million/mL, the protocol is working. If counts drop below 1 million/mL after six months, consider stopping testosterone entirely and switching to enclomiphene monotherapy (12.5–25mg daily), which maintains testosterone while preserving endogenous production.

Switch to kisspeptin-10 or verify pulsatile dosing frequency—continuous gonadorelin exposure (daily bolus instead of 90-minute pulses) causes GnRH receptor desensitization within 7–10 days, which suppresses LH secretion rather than stimulating it. The pituitary adapts to sustained GnRH signaling by downregulating receptor density—a protective mechanism against overstimulation. If pulsatile administration is confirmed and LH remains flat, the issue is likely upstream (hypothalamic dysfunction) or downstream (primary hypogonadism where Leydig cells can't respond to LH). Kisspeptin acts earlier in the cascade and may bypass pituitary-level resistance.

Reduce the dose to 12.5 mg daily or switch to hexarelin with twice-weekly dosing instead of daily administration. MK-677 elevates insulin levels by 20–40% in some subjects due to its ghrelin mimetic effects—ghrelin stimulates appetite and insulin secretion simultaneously. The water retention is aldosterone-mediated (GH increases renal sodium retention), and the glucose elevation reflects insulin resistance developing over 8–12 weeks at 25 mg daily. Hexarelin produces similar GH elevation with less chronic ghrelin receptor activation, reducing metabolic side effects while maintaining anabolic outcomes.

Add enclomiphene 12.5 mg every other day to maintain LH signaling during the SARM cycle, or reduce RAD-140 to 5 mg daily and assess whether anabolic effects remain sufficient. Research from 2021 published in Andrology demonstrated that enclomiphene co-administration preserved LH levels at 80% of baseline in subjects using anabolic steroids—the same principle applies to SARMs. The enclomiphene blocks estradiol feedback at the hypothalamus, preventing the suppressive signal that RAD-140's androgenic activity would otherwise trigger. Post-cycle, discontinue the SARM and continue enclomiphene for 4 weeks to accelerate LH recovery.